. 2022 Oct 28;10:1031306. doi: 10.3389/fpubh.2022.1031306

Table 1.

The definition of SGLT2i and GLP-1 RA preference criteria based on the ADA recommendations (25).

Patients' criteria to likely benefit from the use of either SGLT2i or GLP-1 RA

SGLT2i for patients with T2DM and one of the following:

1–Chronic kidney disease.
2–Established ASCVD.
3–High-risk of ASCVD; defined as having a 10-year ASCVD risk score ≥20%, having stenosis, or left ventricular hypertrophy.
4–BMI ≥ 27 Kg/m².
5–HFrEF (< EF <45%).
6–Patient is on two other antidiabetic medications*.
GLP-1 RA for patients with T2DM and one of the following:
1–Chronic kidney disease.
2–Established ASCVD.
3–High-risk of ASCVD; defined as having a 10-year ASCVD risk score ≥20%, having stenosis, or left ventricular hypertrophy.
4–BMI ≥ 27 Kg/m².
5–Patient is on insulin.
6–Patient is on two other antidiabetic medications^*.

SGLT2i, Sodium–glucose Cotransporter−2 Inhibitors; GLP−1 RA, Glucagon–like Peptide−1 Receptor Agonists; ASCVD, Atherosclerotic Cardiovascular Disease; T2DM, Type 2 diabetes mellitus, BMI, body mass index, HFrEF, Heart failure with reduced ejection fraction; Stenosis, Diagnosis of stenosis of the carotid, coronary, or lower extremity with > 50%. *This is used to indicate the patient has uncontrolled T2DM.